Analysts Offer Predictions for ARCT Q3 Earnings

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) – Research analysts at Leerink Partnrs issued their Q3 2025 earnings estimates for Arcturus Therapeutics in a note issued to investors on Wednesday, January 22nd. Leerink Partnrs analyst L. Nsongo forecasts that the biotechnology company will post earnings of ($0.80) per share for the quarter. The consensus estimate for Arcturus Therapeutics’ current full-year earnings is ($2.31) per share.

Several other equities research analysts also recently weighed in on ARCT. HC Wainwright reissued a “buy” rating and issued a $63.00 price target on shares of Arcturus Therapeutics in a report on Monday, January 13th. Cantor Fitzgerald reissued an “overweight” rating on shares of Arcturus Therapeutics in a research report on Monday, December 16th. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $66.75.

Arcturus Therapeutics Trading Up 2.0 %

Shares of ARCT opened at $16.74 on Thursday. Arcturus Therapeutics has a 12 month low of $14.30 and a 12 month high of $45.00. The stock has a fifty day moving average price of $17.32 and a 200-day moving average price of $19.76.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.70) by $0.44. Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. The firm had revenue of $41.67 million during the quarter, compared to analyst estimates of $49.16 million. During the same quarter in the previous year, the business posted ($0.61) EPS.

Institutional Investors Weigh In On Arcturus Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. nVerses Capital LLC purchased a new position in shares of Arcturus Therapeutics during the 3rd quarter valued at approximately $42,000. China Universal Asset Management Co. Ltd. increased its holdings in Arcturus Therapeutics by 64.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 5,201 shares of the biotechnology company’s stock valued at $121,000 after buying an additional 2,038 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Arcturus Therapeutics in the second quarter worth about $142,000. Point72 DIFC Ltd purchased a new stake in shares of Arcturus Therapeutics during the 2nd quarter worth about $188,000. Finally, SG Americas Securities LLC purchased a new stake in shares of Arcturus Therapeutics during the 3rd quarter worth about $191,000. 94.54% of the stock is owned by hedge funds and other institutional investors.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.